Candida secured a last-minute rescue deal on November 10, 2026, when private equity firm Muri Capital agreed to purchase the Auckland-based envelope manufacturer, averting a total wind-up and preserving local production.
Here is the math: The acquisition halts closure plans that were set for November, reinstating multiple manufacturing jobs and keeping critical equipment on domestic soil rather than shipping the entirety across the Tasman to Australia.
- Immediate Continuity: Muri Capital director Guy Phillips confirmed zero pause in production when the firm officially takes over operations on November 30, 2026.
- Living Wage Commitment: Returned staff will retain or improve their current compensation as part of the transition under the new ownership.
- Supply Chain Retention: The deal protects specialized manufacturing skills built over decades, ensuring domestic capacity ahead of the peak Christmas season.
The manufacturing branch faced imminent closure earlier in the month, with Candida management pointing to mounting operational expenses and difficult domestic and international economic headwinds. The initial wind-up proposal threatened to extinguish decades of specialized manufacturing capability in Auckland while shifting remaining assets to Candida Australia, which operates independently across the Tasman.
Instead, New Zealand-owned private equity firm Muri Capital stepped in following the initial corporate announcement, locking down an acquisition for an undisclosed sum. Muri Capital brings direct industry familiarity to the transaction through its ownership of Touchprint, an independent print and manufacturing enterprise.
“When you have such good envelopes being manufactured in our own country, we had to get in behind the team and the product. Our hope is that customers will agree and maintain Candida as their preferred supplier of envelopes,” Phillips stated to the NZ Herald.
The previous corporate entity had already initiated redundancy proceedings before the buyout materialized. Muri Capital is currently negotiating with former employees to re-engage as many workers as possible.
While management could not confirm a specific total headcount for the reinstated workforce, Phillips indicated that many staff members would return. Original start dates will be honoured for personnel brought back on permanent contracts, alongside fixed-term agreements for others.
“For us, this is about backing a good New Zealand business, keeping manufacturing capability here and giving Candida the opportunity to grow,” Phillips said.
As a recognized living wage employer, Muri Capital confirmed that returning personnel would receive pay scales matching or exceeding their previous compensation.
| Operational Metric | Previous Status | Muri Capital Transition Plan |
|---|---|---|
| Ownership Structure | Candida (Branch wind-up proposed) | Muri Capital (Private equity acquisition) |
| Effective Takeover Date | November 2026 (Winding up) | November 30, 2026 (Zero pause in output) |
| Staff Compensation | Redundancy processing | Living wage or better, original start dates kept |
| Market Focus | Partial asset transfer to Australia | Retaining domestic production for local orders |
Candida will retain its distinct brand identity and operate as a standalone business under the new ownership umbrella.
Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute financial advice.
